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 Simvastatin Suppresses Airway IL-17 and 
Upregulates IL-10 in Patients With Stable COPD 
 Kittipong  Maneechotesuwan ,  MD ,  PhD ;  Adisak  Wongkajornsilp ,  MD ,  PhD ;  Ian M.  Adcock ,  PhD ; 
and  Peter J.  Barnes ,  DM ,  Master FCCP 
 BACKGROUND:  Statins have immunomodulatory properties that may provide benefi cial eff ects 
in the treatment of COPD. We investigated whether a statin improves the IL-17/IL-10 imbal-
ance in patients with COPD, as has previously been demonstrated in patients with asthma. 
 METHODS:  Th irty patients with stable COPD were recruited to a double-blind, randomized, 
controlled, crossover trial comparing the eff ect of simvastatin, 20 mg po daily, with that of a 
matched placebo on sputum infl ammatory markers and airway infl ammation. Each treatment 
was administered for 4 weeks separated by a 4-week washout period. Th e primary outcome 
was the presence of T-helper 17 cytokines and indoleamine 2,3-dioxygenase (IDO) in induced 
sputum. Secondary outcomes included sputum infl ammatory cells, FEV 1 , and symptoms using 
the COPD Assessment Test (CAT). 
 RESULTS:  At 4 weeks, there was a significant reduction in sputum IL-17A, IL-22, IL-6, and 
CXCL8 concentrations (mean difference,  2 16.4 pg/mL,  P  5 .01;  2 48.6 pg/mL,  P  , .001; 
 2 45.3 pg/mL,  P  5 .002; and  2 190.9 pg/mL,  P  5 .007, respectively), whereas IL-10 concentra-
tions, IDO messenger RNA expression (fold change), and IDO activity (kynurenine to trypto-
phan ratio) were markedly increased during simvastatin treatment compared with placebo 
treatment periods (mean diff erence, 24.7 pg/mL,  P  , .001; 1.02,  P  , .001; and 0.47,  P  , .001, 
respectively). Th e absolute sputum macrophage count, proportion of macrophages, and CAT 
score were reduced aft er simvastatin compared with placebo (mean diff erence,  2 0.16  3 10 6 , 
 P  5 .004;  2 14.1%,  P  , .001; and  2 3.2,  P  5 .02, respectively). Values for other clinical outcomes 
were similar between the simvastatin and placebo treatments. 
 CONCLUSIONS:  Simvastatin reversed the IL-17A/IL-10 imbalance in the airways and reduced 
sputum macrophage but not neutrophil counts in patients with COPD. 
 TRIAL REGISTRY: ClinicalTrials.gov; No.: NCT01944176; www.clinicaltrials.gov 
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 ABBREVIATIONS:  CAT  5 COPD Assessment Test; CVD  5 cardiovas-
cular disease; ELISA  5 enzyme-linked immunosorbent assay; GOLD  5 
Global Initiative for Chronic Obstructive Lung Disease; hsCRP  5 
high-sensitivity C-reactive protein; ICS  5 inhaled corticosteroid; 
IDO  5 indoleamine 2,3-dioxygenase; IQR  5 interquartile range; Kyn  5 
kynurenine; LABA  5 long-acting  b 2 -agonist; [M 1 H] 1  5 protonated 
species; N-ac-PGP  5 N-acetyl-proline-glycine-proline; STATCOPE  5 
Simvastatin in the Prevention of COPD Exacerbations; Th   5 T helper; 
Treg  5 T regulatory; Tryp  5 tryptophan 
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 Cytokines play a critical role in the pathobiologic processes 
of COPD, including altered innate immune response, 
chronic infl ammation, emphysema, and small airway fi bro-
sis. 1 Proinfl ammatory cytokines of potential importance 
include tumor necrosis factor- a , interferon- g , IL-1 b , IL-17, 
and IL-6. COPD has been associated with an increased 
IL-17 response directed against innocuous antigens. 2 IL-17 
promotes chronic airway infl ammation by primarily 
acting on the lung epithelium through the upregulation 
of proinfl ammatory cytokines and chemokines. 3,4 Genetic 
deletion of IL-17A attenuated cigarette smoke-induced 
infl ammation and alveolar type 2 apoptosis in mice. 5 Th e 
expression of IL-17A in human bronchial submucosa was 
signifi cantly increased in patients with COPD compared 
with healthy control subjects and normal smokers. 6,7 
 Accumulating evidence suggests that CD4  1  T cells, 
including T regulatory (Treg) cells and T-helper (Th )17 
cells, possess a greater degree of plasticity in their diff er-
entiation options than previously appreciated. 8 It appears 
that expression of Foxp3 by Treg cells or ROR g t by 
Th 17 cells may not be stable. 8 Th 17 cells produce IL-17 and 
IL-22, thereby boosting infl ammation, while Treg cells 
express IL-10 and tumor growth factor- b , suppressing 
infl ammation at least in part through the immunosup-
pressive eff ects of indoleamine 2,3-dioxygenase (IDO). 
Th e induction of IDO-enhanced tryptophan (Tryp) catab-
olism into kynurenine (Kyn), which can inhibit the accu-
mulation of Th 1 and Th 17 cells at the site of infl ammation 
and, therefore, attenuate the degree of infl ammation. 9 
Th is may explain the imbalance between Th 17 and Treg 
cytokines in COPD that we have previously documented. 10 
We have shown that sputum IL-17A concentrations are 
associated with COPD severity and inversely correlated 
with IL-10 concentrations, with reduced expression of the 
immunosuppressive enzyme IDO and its bioactivity. 11 
Th is may contribute, in part, to a further enhancement 
of airway infl ammation in COPD. 
 Statins are 3-hydroxy-3-methyl-glutarylcoenzyme A 
reductase inhibitors that have been clinically used as 
lipid-lowering agents. Statins, however, have additional 
pleiotropic pharmacologic eff ects, including antiinfl am-
matory, antioxidant, and immunomodulatory activities 
in vitro and in vivo. 12-15 Th e immunomodulatory eff ects 
of statins on Th 17 cell- and IL-17-mediated infl ammatory 
responses have been well established in autoimmune dis-
eases, including multiple sclerosis in humans and exper-
imental autoimmune encephalomyelitis in mice. Statins 
mediate their action via suppression of Th 17 diff erentia-
tion with the concurrent induction of Treg diff erentiation. 16 
Emerging evidence suggests that statins inhibit the 
release of airway neutrophilic mediators (CXCL8, IL-6, 
and granulocyte-macrophage colony-stimulating factor) 
from bronchial epithelial cells and suppress their upreg-
ulation by IL-17. 17 Interestingly, all of these additional 
actions may counteract the neutrophilic infl ammation-
promoting eff ects of IL-17 in COPD. To date, there has 
been a paucity of studies exploring the antiinfl ammatory 
eff ects of statins in COPD and particularly on the reversal 
of IL-17A/IL-10 or Th 17/Treg imbalance. 
 We conducted a double-blind, placebo-controlled cross-
over study to ascertain the eff ect of simvastatin on Th 17 
cytokines and Th 17-polarizing cytokine expression and 
chronic airway infl ammation in COPD. To our knowledge, 
this study is the fi rst to show that simvastatin inhibits IL-17, 
IL-22, CXCL8, and IL-6, but enhances IL-10, IDO mes-
senger RNA expression, and IDO biologic activity. How-
ever, these eff ects of simvastatin were not associated with 
the attenuation of airway neutrophilia but unexpectedly 
resulted in a marked decrease in macrophage numbers. 
 Materials and Methods 
 Study Design and Assignment 
 The study was a 4-week, randomized, double-blind, crossover study 
comparing the eff ect of oral simvastatin treatment (20 mg daily) with 
that of a matched placebo on sputum cytokine biomarkers and airway 
infl ammation in COPD. Aft er a 2-week run-in period, each treatment 
was administered to randomized patients for 4 weeks, separated by a 
4-week washout period. Researchers and participants were blinded to 
allocation and had no access to the randomization code held by the data 
center until completion of the study. Th e conduct of this study complied 
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with the Declaration of Helsinki. The study was approved by the 
Siriraj Institutional Review Board (Si323/2013). Written informed 
consent was obtained from each study patient prior to entry into the 
trial. Th e study was listed on all appropriate clinical trial registries. 
 During the 2-week run-in period and throughout the study, subjects 
continued their usual COPD medication and withdrew statin therapy for 
4 weeks prior to the study entry if they were taking regular treatment. 
Further visits were undertaken at randomization and after 4 weeks 
(phase 1). Aft er a washout period of 4 weeks, phase 2 of the crossover 
was started with a visit after 4 weeks. At each visit, spirometry was 
performed. Before and aft er each treatment period, sputum induction 
was performed and blood samples were taken to measure lipid levels 
and liver function. Tablets were counted at the end of each treatment 
period as a measure of treatment adherence. 
 Patients 
 Patients with COPD aged 45 to 80 years were recruited from the COPD 
Outpatients Clinic at Siriraj Hospital. Patients with COPD met the 
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following inclusion criteria: current or ex-smokers with a   10 pack-year 
history; postbronchodilator FEV 1 to FVC ratio  , 70% and FEV 1  , 80% 
and   50% of predicted normal values (GOLD [Global Initiative for 
Chronic Obstructive Lung Disease] grade 2) at visit 1 (screening); and 
clinically stable as defi ned by no exacerbations in the previous 6 weeks. 
 Key exclusion criteria were a primary diagnosis of asthma; history 
of signifi cant diseases other than COPD, including TB, lung cancer, 
and HIV; acute worsening of COPD that required treatment within 
6 weeks prior to screening or between the screening and baseline 
visits; cognitive impairment; recent cardiovascular and cerebrovascular 
diseases within 6 months prior to study entry; current or previous use 
of immunosuppressive agents; and current administration of macrolides, 
azole antifungal drugs, and amlodipine. 
 Recruited study participants who were taking certain COPD medica-
tions at screening (ie, tiotropium, long-acting  b 2 -agonists [LABAs], 
combination corticosteroid and LABA products, theophylline, oral 
 b 2 -agonists) were permitted to continue these medications through-
out the trial to maintain their clinical stability, with the exception of 
the study visit. Study participants were required to withhold all COPD 
medications (including inhaled corticosteroids [ICSs] and short-acting 
bronchodilators) for at least 8 h before the baseline visit and all subse-
quent study treatment visits. 
 At visit 2, study participants were randomized to one of two possible 
treatment sequences. Each sequence included either 4-week adminis-
tration of simvastatin (20 mg/d) or placebo in a double-blind manner. 
Patients returned to the clinic for washout at visit 3, for treatment at 
visit 4, and for a final visit at visit 5. There was a washout interval 
between treatments of 4 weeks. 
 Measurements 
 Demographic measurements were recorded on the fi rst clinical visit 
(visit 1 screening). Induced sputum and blood samples were collected 
before and aft er treatment periods for analysis of sputum cytokines and 
diff erential leukocyte count and assessment of lipid profi les and high-
sensitivity C-reactive protein (hsCRP). Spirometry, COPD Assessment 
Test (CAT) score, and impulse oscillometry were measured at all study 
visits. Th e primary end point was IL-17A, IL-10, and IL-6 levels, and 
IDO activity. Secondary end points included CAT scores, sputum 
neutrophil count, and postbronchodilator FEV 1 . 
 Sputum Induction and Processing 
 Sputum induction was performed as previously described. 11 Th e super-
natants were kept frozen at  2 70°C until further analysis. For immuno-
cytochemistry, cytospins were fi xed with 4% paraformaldehyde (BDH 
Ltd) and stored at  2 20°C. Total cell counts were recorded with a hemo-
cytometer, using Kimura staining. Cell viability was determined by 
Trypan blue exclusion before cytospins were undertaken. Th e slides 
were stained with May-Grunwald-Giemsa stain and differential cell 
counts were made by a blinded observer. A total of 400 infl ammatory 
cells were counted on two slides for each sample in a blinded manner. 
Diff erential cell counts are expressed as the percentages of total infl am-
matory cells. Samples with cell viability  . 70% and  , 30% squamous 
cell contamination were considered adequate for analysis. 
 Cytokine Assays 
 For detection of human IL-6, CXCL-8, IL-10, IL-17A, IL-22, and 
IL-23, sandwich enzyme-linked immunosorbent assays (ELISAs) were 
performed according to the manufacturer’s instructions (Abcam plc). 
Th e sensitivity was 0.8 pg/mL for IL-6, 1 pg/mL for CXCL8, 1.3 pg/mL 
for IL-10, 3 pg/mL for IL-17A, 5 pg/mL for IL-22, and  , 20 pg/mL for 
IL-23. Cytokine output was normalized to the concentration of protein. 
It should be noted that the standard range of the ELISA assay used 
in this study was lower than that of the ELISA assays used by previ-
ous studies, possibly resulting in the baseline levels of some cytokines 
reported in this study being different from those reported in other 
studies. In addition, the differences of cytokine measurements in our 
study from others might be explained by the nature of our recruits. Th e 
majority of our subjects were treated with ICSs, whereas other studies 
recruited steroid-naive patients with COPD, those with mild COPD 
without treatment, or minority of patients with steroid-treated severe 
COPD. 18,19 Th e diff erence in the nature of steroid use might contribute 
to the low basal levels of several cytokines. 
 RNA Isolation and Real-Time Reverse Transcription-
Polymerase Chain Reaction Analysis 
 Total RNA was extracted from whole sputum cell pellets by using 
an RNeasy Mini kit (Qiagen NV) according to the manufacturer’s 
instructions. Total RNA was reverse transcribed into cDNA by using 
Improm-II Reverse Transcription system (Promega Corporation). Real-
time reverse transcription-polymerase chain reaction was performed 
with FastStart Universal SYBR Green Master (Roche Holding AG) with an 
ABI PRISM 7900 thermal cycler (Th ermo Fisher Scientifi c Inc) accord-
ing to the manufacturer’s instructions. Th e following IDO primers were 
purchased from First BASE Laboratory (BASE Life Sciences Holdings): 
sense: AGT CCG TGA GTT TGT CCT TTC AA, and antisense: TTT 
CAC ACA GGC GTC ATA AGC T; and glyceraldehyde-3-phosphate 
dehydrogenase sense: GAA ATC CCA TCA CCA TCT TCC, and anti-
sense: AAA TGA GCC CCA GCC TTC TC. Th e 7300 System SDS soft -
ware version 1.4.0.25 (Th ermo Fisher Scientifi c Inc) was used to analyze 
the relative quantity of the target cDNA, according to the  D D Ct method. 
 Liquid Chromatography-Mass Spectrometry 
Analysis of L-Tryp and L-Kyn 
 Analysis of L-Tryp and L-Kyn was performed using a validated high-
performance liquid chromatography with tandem mass spectrometry 
method as previously described. 20 Briefl y, 3-nitro- l -tyrosine was added 
to each sample as an internal standard, and protein precipitation was per-
formed using 10% trichloroacetic acid. Chromatographic separation of 
the subsequent organic layer was carried out on liquid chromatography-
tandem mass spectrometry with C18, 2.5 mm (50  3 3.0 mm internal 
diameter). A mobile phase consisting of acetonitrile and 0.1% formic 
acid (gradient condition) was delivered at a fl ow rate of 0.2 mL/min. 
Mass spectra were obtained using a Quattro Premier XE mass spec-
trometer (Micromass; Waters Corporation) operated in multiple reaction 
monitoring mode. Sample introduction and ionization were performed 
by electrospray ionization in the positive ion. Th e mass transition ion 
pair for L-Tryp protonated species ([M 1 H] 1 ) and L-Kyn L-Tryp 
[M 1 H] 1 ions was selected as mass to charge ratio 205.08  . 188.00 
and 205.08  . 146.08, respectively. The mass transition ion-pair for 
3-nitro- l -tyrosine [M 1 H] 1 ions was selected as mass to charge ratio 
227.02  . 181.03. The data acquisition was ascertained by Masslynx 
4.1 soft ware (Waters Corporation). Th e lower limit of detection for L-Tryp 
and L-Kyn in sputum supernatants were 0.05  m g/mL and 0.15  m g/mL, 
respectively. Th e best linear fi t was achieved with a 1/x weighting factor, 
showing a mean correlation coeffi  cient   0.998. 
 Statistical Analyses 
 Baseline characteristics were described by number and percentage of 
patients for categorical variables and mean (  SD) for continuous vari-
ables. Response to simvastatin on lung function, induced sputum, and 
mediator levels vs placebo was assessed by general linear model for the 
standard 2  3 2 crossover design. When variables were unsuitable for 
this, the within-patient treatment diff erences were calculated and then 
analyzed by a paired  t test for parametric and Wilcoxon signed rank 
test for nonparametric data. Th e eff ects of ICS treatment and smoking 
status on the response to simvastatin were analyzed by an unpaired 
 t test. Signifi cance at a level of 5% was accepted for the primary end point. 
 A sample size of 21 was calculated to have 80% power to detect a dif-
ference in means of 0.23 in IDO activity (the ratio of Kyn to Tryp) and 
15 pg/mL in sputum IL-17A (primary end point), assuming an SD of 
difference of 0.35 and 20 pg/mL using a paired  t test with a 5% two-
sided signifi cance level. A total of 30 patients were recruited to ensure 
that 21 patients completed the study. All data were analyzed using PASW 
statistics 18 (SPSS; IBM Corporation).  
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 Results 
 Recruitment and Baseline Characteristics 
 Screening visits were arranged for 30 patients; 26 patients 
were randomized to therapy because four were excluded 
prior to randomization ( Fig 1 ). Of the 26 patients, 
21 completed the treatment phase and fi ve discontinued 
the study before completion, as indicated in  Figure 1 . 
Baseline demographic and clinical characteristics of 
the patients are shown in  Table 1 and baseline infl am-
matory marker levels in  Table 2 . Almost all patients 
had symptomatic GOLD B COPD, according to GOLD 
classifi cation. Distributions of baseline characteristics 
were similar for patients starting with placebo and those 
starting with simvastatin. 
 Changes in Inﬂ ammatory Biomarkers 
 IL-17 and IL-22:  To determine the eff ect of simvastatin 
on Th 17 signature cytokine response in the airways of 
patients with COPD, IL-17A and IL-22 were quantifi ed 
on the protein level in sputum supernatants of simvastatin- 
and placebo-treated patients with COPD. Patients with 
COPD who were treated with simvastatin showed a 
signifi cant decrease of IL-17A levels compared with the 
baseline levels prior to treatment, whereas there was no 
signifi cant reduction in control subjects treated with 
placebo (median [interquartile range (IQR)], 9.1 pg/mL 
[5.4-21.2 pg/mL] vs 32.3 pg/mL [14.5-45.5 pg/mL], 
 P  5 .0001; 22.5 pg/mL [8.0-39.8 pg/mL] vs 20.2 pg/mL 
[11.6-48.3 pg/mL],  P  5 .48, respectively). In addition, 
the magnitude of the reduction in sputum IL-17A 
concentrations was signifi cant in patients with COPD 
treated with simvastatin compared with control subjects 
receiving placebo (mean diff erence,  2 16.4 pg/mL; 
95% CI,  2 28.3 to  2 4.4;  P  5 .01) ( Fig 2A ,  Table 3 ). Th is 
suppression was not dependent upon the sequence of 
treatments either with simvastatin fi rst and placebo sec-
ond or vice versa ( P  5 .74) ( Table 3 ). Th ere was no signif-
icant diff erences in the IL-17A response to simvastatin 
in patients taking ICSs compared with those not taking 
ICSs and between ex-smokers and current smokers 
( P  5 .9 and  P  5 .5, respectively). Similarly, the magnitude 
of the reduction in sputum IL-22 levels was signifi cant in 
patients with COPD treated with simvastatin compared 
with control subjects receiving placebo (mean diff er-
ence,  2 48.6 pg/mL; 95% CI,  2 58.4 to  2 38.9;  P  , .001) 
( Fig 2B ,  Table 3 ). IL-22 response to simvastatin treat-
ment was not aff ected by ICS treatment and smoking 
status ( P  5 .09 and  P  5 .4, respectively). However, 
IL-23 was undetectable in sputum (data not shown). 
 IL-10 and IDO:  Patients with COPD treated with simva-
statin had higher concentrations of IL-10 in sputum 
supernatants compared with the baseline levels, whereas 
there was no signifi cant increase of IL-10 in patients with 
COPD who received placebo (median [IQR], 28.8 pg/mL 
[17.5-41.7 pg/mL] vs 7.2 pg/mL [5.9-9.0 pg/mL],  P  , .001; 
8.3 pg/mL [6.5-10.0 pg/mL] vs 8.1 pg/mL [6.6-9.5 pg/mL], 
 P  5 .78, respectively). In addition, the magnitude of the 
increase in IL-10 levels was signifi cant in patients with 
COPD treated with simvastatin compared with subjects 
treated with placebo (mean diff erence, 24.7 pg/mL; 
 Figure 1 – Flow of subjects through 
the study. 
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 TABLE 1  ]  Demographic Data and Clinical 
Characteristics of Study Subjects 
Clinical Parameters
All Patients 
(N  5 21)
Age, y 68.4   7.8
Smoking pack-y 36.7   28.9
Ex-smoker to current smoker ratio, No. 16:5
Pre-BD FEV 1 /FVC, % 53.9   11.5
Post-BD FEV 1 /FVC, % 55.7   11.6
Post-BD FEV 1 , L 1.55   0.6
Post-BD FVC, L 2.7   0.7
 D FEV 1 , mL 115.2   108.0
BD reversibility, % 9.5   8.9
D LCO , mL/mm Hg/min 57.4   21.2
D LCO /V A , mL/mm Hg/min/L 62.4   14.2
ICS/LABA use, % 38.1
LAMA use, % 4.7
Triple therapy, % 33.3
BD po, % 38.1
Previous statin therapy, % 38.1
 Data are presented as mean   SD unless otherwise indicated. BD  5 bron-
chodilator;  D  5 change in; D LCO  5 diﬀ using capacity of the lung for 
carbon monoxide; ICS  5 inhaled corticosteroid; LABA  5 long-acting 
 b 2 agonist; LAMA  5 long-acting muscarinic antagonist; V A  5 alveolar 
volume. 
95% CI, 15.9-33.6;  P  , .001) ( Fig 3A ,  Table 3 ). Th is eff ect 
was not dependent upon the sequence of treatments 
between simvastatin and placebo ( P  5 .65). Patients 
without ICS treatment had a signifi cantly greater response 
of IL-10 to simvastatin than those with ICS treatment, 
whereas smoking status did not aff ect IL-10 response 
( P  5 .037 and  P  5 .9, respectively). IL-10 is an enhancer 
of IDO expression. We demonstrated an increase in IDO 
messenger RNA expression with its enzymatic activity 
with simvastatin treatment (mean diff erence in fold 
change, 1.02 [95% CI, 0.75-1.3],  P  , .001; 0.47 [95% CI, 
0.28-0.65],  P  , .001, respectively) ( Figs 3B, 3C ,  Table 3 ). 
 IL-6 and CXCL8:  Th e sputum concentration of IL-6 was 
signifi cantly reduced aft er simvastatin while reciprocally 
increased aft er placebo treatment compared with the 
baseline (median [IQR], 29.6 pg/mL [9.3-34.2 pg/mL] 
vs 37.2 pg/mL [18.8-68.3 pg/mL],  P  , .001; 54.0 pg/mL 
[16.2-79.5 pg/mL] vs 24.4 pg/mL [10.7-52.3 pg/mL], 
 P  5 .02). Th e suppressive eff ect of simvastatin therapy was 
also refl ected by a signifi cant reduction in concentrations 
of sputum CXCL8 compared with placebo treatment 
(mean   SD, 447.3   205.1 pg/mL vs 612.7   262.4 pg/mL, 
 P  , .001; 627.0   225.7 pg/mL vs 602.9   239.9 pg/mL, 
 P  5 .7, respectively). Th e magnitude of the reduction 
in IL-6 and CXCL8 concentration was signifi cant in 
patients with COPD treated with simvastatin compared 
with subjects treated with placebo (mean diff erence, 
 2 45.3 pg/mL [95% CI,  2 71.3 to  2 19.4 pg/mL],  P  5 .002; 
 2 190.9 pg/mL (95% CI,  2 324.1 to  2 57.7),  P  5 .007, 
respectively) ( Figs 4A, 4B ,  Table 3 ). Th is suppressive 
eff ect was not dependent upon the sequence of treatments 
in a crossover-designed manner ( P  5 .77 for IL-6 and 
 P  5 .87 for CXCL8). Similarly, ICS treatment and 
smoking status did not infl uence IL-6 and CXCL8 
responses to simvastatin ( P  5 .05 and  P  5 .09, respectively, 
for IL-6;  P  5 .06 and  P  5 .3, respectively, for CXCL8). 
 Induced Sputum Cytology 
 Th e total cell counts recovered from sputum were similar 
aft er simvastatin and aft er placebo treatment ( Table 3 ). 
Aft er 4 weeks, the mean absolute and relative sputum 
macrophage counts were signifi cantly reduced aft er 
simvastatin compared with placebo (mean absolute 
diff erence,  2 0.16  3 10 6 [95% CI,  2 0.26 to  2 0.06], 
 P  5 .004;  2 14.1% [95% CI,  2 21.0 to  2 7.1],  P  , .001) 
( Figs 5A, 5B ,  Table 3 ). Th ere was a reciprocal increase in 
the relative proportion of sputum airway epithelial cells 
(mean proportion diff erence, 7.6%; 95% CI, 2.3-12.9; 
 P  5 .007) ( Table 3 ), but there was no signifi cant changes 
in the absolute count of these cells or the counts and 
proportions of the other sputum cell phenotypes under 
simvastatin treatment. 
 Changes in Clinical Outcomes 
 Changes in clinical outcomes aft er simvastatin treatment 
are listed in  Table 4 . At 4 weeks, the change in mean 
CAT score aft er simvastatin compared with placebo 
treatment periods was statistically signifi cant (mean dif-
ference,  2 3.2; 95% CI,  2 6.0 to  2 0.4;  P  5 .02) ( Table 4 ). 
No statistically signifi cant eff ect of simvastatin was seen 
in post-salbutamol FEV 1 , post-salbutamol FVC, or 
lung resistance at 5 Hz to 20 Hz compared with placebo 
treatment ( Table 4 ). 
 Changes in Biochemical Markers 
 Th ere was no signifi cant change in hsCRP levels between 
treatment groups (mean diff erence,  2 7.7 mg/dL; 
95% CI,  2 19.3 to 4.0;  P  5 .18) ( Table 5 ). Th e biochemical 
eff ects of simvastatin therapy were refl ected in a signifi -
cant reduction in concentration of serum low-density 
lipoprotein cholesterol (mean diff erence,  2 47.6 mg/dL; 
95% CI,  2 61.5 to  2 33.7;  P  , .001), but not high-density 
lipoprotein cholesterol (mean diff erence, 1.1 mg/dL; 
95% CI,  2 5.9 to 8.1;  P  5 .74) ( Table 5 ). Th ere were no 
signifi cant diff erences in mean bilirubin, aspartate 
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aminotransferase, alanine aminotransferase, blood urea 
nitrogen, creatinine, and creatine phosphokinase levels. 
No signifi cant adverse events occurred in patients 
taking simvastatin or in those receiving placebo. 
 Discussion 
 Th is study has demonstrated the ability of simvastatin 
to suppress Th 17 cytokines (IL-17 and IL-22), CXCL8, 
and IL-6, with concomitant enhancement of IL-10 pro-
duction and IDO expression and activity in patients 
with COPD. Surprisingly, simvastatin had no signifi cant 
eff ect on neutrophilic airway infl ammation, although it 
did suppress macrophage numbers and improved CAT 
symptom score. 
 To our knowledge, no previous study has investigated 
the antiinfl ammatory eff ects of statins in COPD. In 
particular, the eff ects on Th 17 cytokines, including IL-17 
and Il-22, have not been investigated and are unknown 
in COPD. 
 Several studies have suggested that COPD may have an 
autoimmune component that is related to Th 17 cells, a 
subset of CD4  1  T cells, present in COPD. 21-23 Peripheral-
blood Th 17 cell count was increased in patients with 
COPD, which was predictive of the severity of airfl ow 
limitation. 24 Th 17 cells release IL-17A, IL-17F, and IL-22, 
all of which have been implicated in the pathogenesis 
of several infl ammatory and autoimmune diseases. 
 Figure 2 – A, B, Th e lowering of spu-
tum IL-17A (A) and IL-22 (B) con-
centrations in response to simvastatin 
treatment to a greater extent than 
placebo. Data are expressed as mean 
(SD).  D  5 change in. 
 TABLE 3  ]  Treatment Differences in Sputum Cytology and Cytokines After 4 Wk of Treatment With Simvastatin 
Compared With Placebo 
Variables Placebo Simvastatin  P Value
Treatment Diﬀ erence, 
Simvastatin  2 Placebo (95% CI)
Eﬀ ects by 
Order  P Value
 D Total cells,  3 10 6 0.01   0.4  2 0.09   0.4 .55  2 0.1 ( 2 0.4 to 0.2) .43
 D Neutrophil,  3 10 6 0.03   0.4 0.02   0.3 .86  2 0.02 ( 2 0.24 to 0.2) .38
 D Neutrophils, % 2.2   8.7 5.8   16.9 .35 3.6 ( 2 4.3 to 11.5) .55
 D Eosinophil,  3 10 6  2 0.005   0.04 0.01   0.09 .44 0.01 ( 2 0.02 to 0.05) .85
 D Eosinophils, %  2 0.85   2.7 1.3   7.3 .17 2.2 ( 2 1.0 to 5.4) .65
 D Macrophage,  3 10 6  2 0.02   0.1  2 0.15   0.1 .004  2 0.16 ( 2 0.26 to  2 0.06) .3
 D Macrophages, %  2 0.9   8.6  2 15.2   15.1  , .001  2 14.1 ( 2 21.0 to  2 7.1) .49
 D Lymphocyte,  3 10 6 0.001   0.0 0.004   0.0 .22 0.003 ( 2 0.002 to 0.01) .08
 D Lymphocytes, % 0.06   0.1 0.3   0.7 .16 0.25 ( 2 0.1 to 0.61) .11
 D Airway epithelial cell,  3 10 6 0.0   0.04 0.08   0.2 .08 0.08 ( 2 0.01 to 0.18) .21
 D Airway epithelial cells, %  2 0.38   2.2 7.2   11.4 .007 7.6 (2.3 to 12.9) .08
 D Sputum IL-17A, pg/mL  2 0.89   18.1  2 17.2   15.4 .01  2 16.4 ( 2 28.3 to  2 4.4) .74
 D Sputum IL-22, pg/mL 6.9   21.9  2 42.0   13.9  , .001  2 48.6 ( 2 58.4 to  2 38.9) .87
 D Sputum IL-10, pg/mL 0.56   2.8 25.4   19.0  , .001 24.7 (15.9 to 33.6) .65
 D Sputum IL-6, pg/mL 23.7   40.7  2 21.6   25.1 .002  2 45.3 ( 2 71.3 to  2 19.4) .77
 D Sputum CXCL8, pg/mL 24.1   296.9  2 165.4   152.0 .007  2 190.9 ( 2 324.1 to  2 57.7) .87
 D IDO mRNA, fold change 0.97   0.4 2.0   0.8  , .001 1.02 (0.75 to 1.3) .6
 D IDO activity, Kyn/Tryp  2 0.17   0.3 0.29   0.3  , .001 0.47 (0.28 to 0.65) .34
 Data are presented as mean   SD. See  Table 1 and  2 legends for expansion of abbreviations. 
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IL-17A is a proinfl ammatory cytokine that regulates 
airway infl ammation and modulates lung and airway 
structural cells in COPD through the recruitment of 
infl ammatory cells, including neutrophils and lympho-
cytes. IL-17A acts on airway epithelial cells, smooth muscle 
cells, and airway fi broblasts to release neutrophil chemoat-
tractants, including CXCL8. 25 In addition, IL-17 exerts 
its eff ect on most parenchymal cells, including macro-
phages and dendritic cells that express IL-17 receptors, 
and IL-17-mediated signaling induces the target cells to 
produce various infl ammatory mediators such as tumor 
necrosis factor- a and IL-6. Studies have shown that the 
expression of IL-17A and IL-22 was increased in the air-
ways of patients with COPD and that IL-22 can promote 
airway infl ammation by acting in synergy with IL-17A. 26,27 
Th ese data suggest that inhibition of Th 17-related cyto-
kines might be a useful strategy for COPD treatment 
but, so far, no studies with anti-IL-17 or anti-IL-17 
receptor antibodies, which are clinically eff ective in 
psoriasis and infl ammatory bowel disease, have been 
reported in patients with COPD. Statins have immuno-
modulatory eff ects on Th 17-mediated human autoimmune 
response in multiple sclerosis by selectively inhibiting 
IL-17 transcription and IL-17A, IL-17F, and IL-22 secre-
tion in Th 17 cells, and by suppressing Th 17-polarizing 
cytokine release by dendritic cells. 28-30 However, little is 
known about these immunomodulatory eff ects of statins 
in patients with COPD. To our knowledge, our results 
have demonstrated for the fi rst time that simvastatin 
could markedly suppress secretion of IL-17A and IL-22, 
which may contribute to decreased IL-6 and CXCL8 
production in the airways of patients with COPD. Th e 
molecular mechanisms of IL-17A and IL-22 suppression 
by simvastatin require further investigation. We postulate 
that there are several mechanisms involving the inhibitory 
eff ects of simvastatin on IL-17A and IL-22. Simvastatin 
can induce SOCS3 expression in dendritic cells that 
results in suppression of Th 17-polarizing cytokine IL-23 
 Figure 3 – A, Th e elevation of sputum 
IL-10 concentrations was greater in 
response to simvastatin treatment 
than placebo. B, Th e same pattern 
was seen in IDO messenger RNA 
concentration. C, IDO activity also 
was elevated in response to simvas-
tatin treatment to a greater extent 
than placebo. Th e data are expressed 
as mean (SD). IDO  5 indoleamine 
2,3-dioxygenase; Kyn  5 kynurenine; 
Tryp  5 tryptophan. See  Figure 2 
legend for expansion of other 
abbreviation. 
 Figure 4 – A, Sputum IL-6 concen-
tration was lower in response to 
simvastatin treatment to a greater 
extent than placebo. B, Th e same 
pattern was seen in CXCL8 concen-
trations. Th e data are expressed as 
mean (SD). See  Figure 2 legend for 
expansion of other abbreviation. 
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release. Th is eff ect is associated with geranylgeranylation-
dependent inhibition of small GTPases, including RhoA, 
Rac1, and Rab1, that control IL-23 production. 30 In addi-
tion, simvastatin can directly inhibit IL-17 gene expres-
sion in CD4  1  T cells in a mevalonate-dependent manner. 28 
 Treg cells exert their immune-suppressive ability, in 
part, through secretion of IL-10. A study has shown 
that the Th 17/Treg imbalance, refl ected by an increased 
IL-17A/IL-10 ratio, exists in mice aft er chronic cigarette-
smoke exposure and in patients with stable COPD, and 
this could play a role in the breakdown of immune self-
tolerance in COPD. 11,31,32 IL-10 transcription and its levels 
in the airways and lung parenchyma correlated inversely 
with the severity of COPD and emphysema extent, 
respectively. 11,33 In contrast, other studies showed no 
signifi cant diff erence in IL-10 levels in BAL from patients 
with COPD compared with smoker control subjects. 34 
Nevertheless, boosting IL-10 production by simvastatin, 
as shown in the present study, might restore an impaired 
immune self-tolerance in patients with COPD. In addi-
tion, simvastatin enhanced the expression of the airway 
immunomodulating enzyme IDO by upregulating its 
transcription and biologic activity, refl ected by the gener-
ation of the Tryp metabolite Kyn. Increased IDO activity 
may lead to Treg cell expansion through the activation 
of aryl hydrocarbon receptors by Kyn. 35 Furthermore, 
accumulation of Kyn resulted in subsequent tolerogenic 
eff ects, including increased Treg cell activity. 36 
 In a mouse model, the neutrophilic alveolitis associated 
with acute lung injury is markedly reduced with lova-
statin treatment. 37 We found no signifi cant reduction in 
the proportion of neutrophils in induced sputum with 
simvastatin treatment, despite a marked suppression 
in CXCL8 and IL-17A levels. Th e absolute neutrophil 
counts were not signifi cantly diff erent between groups, 
suggesting that the increased percentage of neutrophils 
aft er simvastatin treatment was because of a decrease in 
percentage of macrophages. In contrast, absolute mac-
rophage counts and the proportion of macrophages were 
markedly reduced in simvastatin treatment compared 
with placebo treatment, possibly resulting from the reduc-
tion in IL-17A that contributes to macrophage recruit-
ment by activating IL-17A receptors on macrophages. 38 
In keeping with the fi nding of a reduced sputum macro-
phage count with simvastatin in COPD, a clinical trial 
in asthma reported atorvastatin treatment, compared 
with placebo, was associated with a reduction in the 
absolute sputum macrophage count. 39 
 Th ere are several possible explanations for the apparent 
lack of clinical eff ects of simvastatin on airway neutro-
philia. The first possibility is that the calculation of 
sample size in this study had been based on signifi cant 
reduction in IDO activity but not the proportion of neu-
trophils and the absolute neutrophil counts. Th e second 
possibility is that there was another chemokine driving 
airway neutrophilia, which could not be suppressed by 
 Figure 5 – A, Absolute macrophage 
counts were lower in response to 
simvastatin treatment to a greater 
extent than placebo. B, A similar 
pattern was seen in the proportion of 
macrophages (% of total cells). Th e 
data are expressed as mean (SD). 
 TABLE 4  ]  The Effect of Simvastatin on Clinical Outcomes 
Variables Placebo Simvastatin  P Value
Treatment Diﬀ erence, 
Simvastatin  2 Placebo (95% CI)
Eﬀ ects by 
Order  P Value
 D CAT score 0.7   5.5  2 2.5   4.1 .02  2 3.2 ( 2 6.0 to  2 0.4) .5
 D Post-BD FEV 1 , L  2 0.01   0.1  2 0.07   0.1 .31  2 0.05 ( 2 0.2 to 0.05) .32
 D Post-BD FVC, L  2 0.04   0.2  2 0.01   0.1 .72 0.03 ( 2 0.1 to 0.2) .82
 D R5-R20  2 0.1   0.9 0.1   0.0 .54 0.2 ( 2 0.48 to 0.88) .25
 Data are presented as mean   SD. CAT  5 COPD Assessment Test; R5-R20  5 lung resistance at 5-20 Hz. See  Table 1 for expansion of other 
abbreviations. 
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simvastatin, such as the tripeptide collagen-derived 
neutrophil chemoattractant N-acetyl proline-glycine-
proline (N-ac-PGP), derived from the breakdown of 
extracellular matrix in the process of alveolar destruction 
emerging in emphysema. N-ac-PGP plays a role in the 
airway and parenchymal neutrophilic infl ammation that 
drives COPD progression and exacerbations. N-ac-PGP 
induced neutrophil chemotaxis and superoxide produc-
tion through CXCR2 receptors. 40-42 In an animal model, 
the administration of N-ac-PGP caused recruitment of 
neutrophils into lungs of control mice, but not CXCR2-
defi cient mice. 40 In contrast, the blockade of N-ac-PGP 
with monoclonal antibody suppressed neutrophil 
responses. N-ac-PGP treatment also caused alveolar 
enlargement and, therefore, N-ac-PGP activity links 
degradation of extracellular matrix with neutrophil 
recruitment in airway infl ammation. Th e considerable 
concentrations of N-ac-PGP were detectable in the 
majority of BAL and sputum samples from patients with 
stable COPD. 40,43 In addition, cigarette-smoke extract-
activated neutrophils can break down collagen to generate 
N-ac-PGP that can activate neutrophils, leading to the 
induction of a self-perpetuating cycle of neutrophil infi l-
tration, chronic infl ammation, and lung emphysema. 44 
Sputum N-ac-PGP levels were dramatically increased at 
the time of an exacerbation of COPD, and azithromycin 
treatment signifi cantly reduced sputum N-ac-PGP levels 
in patients with COPD. 45 Suppression of N-ac-PGP may 
be one of the mechanisms whereby macrolides reduce 
COPD exacerbations in a clinical trial. 46 All these data 
raise the possibility that N-ac-PGP contributes to airway 
neutrophilia in patients with COPD. In addition, the 
majority of the patients with COPD in this study were 
current smokers. It is possible, therefore, that persistent 
extracellular N-ac-PGP generation induces relentless 
neutrophilic airway inflammation that is resistant to 
statin therapy. Other mechanisms driving neutrophilic 
infl ammation in COPD, such as leukotriene B4  or com-
plements, may not be suppressed by a statin, but this 
requires further studies. 
 Statins reduce the recruitment of neutrophils and mac-
rophages into the lung. 47,48 Our results extend the previous 
fi ndings that the mechanisms by which statins suppress 
the recruitment of neutrophils and macrophages into the 
lung are possibly mediated through the inhibition of Th 17 
cytokines and CXCL8 that could mediate the recruitment. 
Th e baseline levels of CXCL8 and IL-6 are associated 
with the frequency of COPD exacerbations. 49,50 During 
COPD exacerbations, CXCL8 and IL-6 levels are signifi -
cantly elevated in the airways, compared with the stable 
phase, 51 suggesting that the development of COPD exac-
erbations is driven by airway infl ammation driven, in 
turn, by these cytokines. Th ese biologic eff ects of statins 
appear to have clinical relevance, as other observational 
studies reported reduced frequency of COPD exacer-
bations, 52-55 and impeded decline of lung function 56 in 
patients taking statins. Th is was supported by the mech-
anistic study showing that IL-17 acted as a mediator of 
IL-1 b -induced neutrophilia in infl uenza-induced COPD 
exacerbations in mice, and inhibition of IL-17 reduced 
neutrophil recruitment to the airways both in the initial 
phase of infection and at the peak of viral replication. 57 
Th erefore, biologic eff ects of statins in COPD demon-
strated in the current study may explain the fi ndings 
from the observational studies. 
 TABLE 5  ]  The Effect of Simvastatin on Biologic Markers 
Sputum Cells Placebo (n  5 21) Simvastatin (n  5 21)  P Value
Treatment Diﬀ erence, 
Simvastatin  2 Placebo (95% CI)
Eﬀ ects by 
Order  P Value
 D hsCRP, mg/dL 3.6   29.3  2 4.0   17.8 .18  2 7.7 ( 2 19.3 to 4.0) .23
 D LDL, mg/dL  2 1.5   24.2  2 49.1   23.8  , .001  2 47.6 ( 2 61.5 to  2 33.7) .51
 D HDL, mg/dL  2 0.2   11.4 0.9   10.0 .74 1.1 ( 2 5.9 to 8.1) .19
 D CPK, U/L 5.3   80.1 34.5   45.8 .2 29.2 ( 2 16.0 to 74.4) .91
 D Total bilirubin, mg/dL 0.02   0.1  2 0.04   0.2 .29  2 0.06 ( 2 0.17 to 0.05) .11
 D Direct bilirubin, mg/dL 0.01   0.09  2 0.01   0.04 .41  2 0.02 ( 2 0.07 to 0.03) .01
 D AST, U/L 8.2   17.8 2.8   6.4 .17  2 5.4 ( 2 13.8 to 2.9) .88
 D ALT, U/L 8.9   25.6 0.9   9.1 .16  2 8.1 ( 2 19.8 to 3.6) .76
 D BUN, mg/dL 0.32   2.7 0.32   3.2 .99 0.01 ( 2 1.8 to 1.8) .81
 D Creatinine, mg/dL 0.05   0.09 0.02   0.1 .26  2 0.03 ( 2 0.09 to 0.03) .52
 Data are presented as mean   SD. ALT  5 alanine aminotransferase; AST  5 aspartate aminotransferase; BUN  5  blood urea nitrogen; CPK  5 creatine 
phosphokinase; HDL  5 high-density lipoprotein; hsCRP  5 high-sensitivity C-reactive protein; LDL  5 low-density lipoprotein. See  Table 1 and  2 legends 
for expansion of other abbreviations. 
 1174  Original Research  [   1 4 8  #  5   C H E S T   N OV E M B E R   2 0 1 5   ] 
 Our results were in agreement with other observa-
tional studies, but diff ered from the results of a placebo-
controlled trial of a statin on COPD exacerbations 
(STATCOPE [Simvastatin in the Prevention of COPD 
Exacerbations]). Previous studies showed the benefi cial 
eff ects of statins on reduced all-cause mortality, 52,58-60 
including that from acute exacerbation, 52,61 reduced 
frequency of COPD exacerbations, especially in patients 
with COPD who had coexisting cardiovascular disease 
(CVD), 52-55,62 and reduced the decline in lung function. 56 
In contrast, in patients with moderate to severe COPD, 
the STATCOPE study found no reduction in exacerba-
tions. 63 A plausible explanation for the discrepancy 
between the fi ndings of the STATCOPE study and that 
of the observational studies and our study is the inclusion 
of a large percentage of patients with COPD with coex-
isting, overt CVD who were “previous statin users” and 
“previous statin nonusers,” but would benefi t from statin 
therapy. 64 Th ese patients are likely to carry a poor prog-
nosis because of one or a combination of the following: 
undertreated pulmonary infl ammation, unrecognized 
systemic infl ammation, or subclinical CVD. 65-67 Th ese 
comorbid phenotypes of COPD are strongly associated 
with an increased risk of hospitalization with acute exac-
erbations and greater mortality. 65-67 Hence, it is possible 
that many patients with COPD who have not been pre-
scribed statins in observational studies are undertreated, 
a hypothesis suggested by STATCOPE investigators to 
explain this discordance. 63 Another explanation for the 
STATCOPE fi ndings is that statin therapy has no eff ect 
on reducing acute exacerbations in patients with COPD 
where coexisting clinical and subclinical CVD has 
been all but excluded. 64 Th e presence of cardiovascular 
comorbidity underlying acute exacerbations of COPD, 
in particular heart failure, 68,69 may intensify the benefi -
cial eff ect of statins. In addition, the selection of patients 
with COPD recruited to the STATCOPE study might 
include a group with much lower risk and who are 
potentially unresponsive to statin treatment. Any benefi t 
in such a group might be masked . 64 Th is was supported 
by the 23% reduction in low-density lipoprotein levels in 
the STATCOPE study, with 40 mg of simvastatin, which 
was less than the expected 36% to 40% reduction nor-
mally observed. 64 Mortality in the placebo arm of the 
STATCOPE study over 3 years was 6%, only one-half 
that reported in the Towards a Revolution in COPD 
Health (TORCH) study over a similar time. 70 Moreover, 
the prevalence of comorbid cardiovascular-related dis-
eases in the STATCOPE participants was not reported 
but is presumably very low or nonexistent. 64 Th e exclusion 
of cardiovascular comorbidity raises questions about the 
generalization of STATCOPE fi ndings to COPD popula-
tions in general, where overt or subclinical CVD may be 
associated with approximately 75% of all subjects. 64 
Since participants in the STATCOPE study were pre-
screened through medical record data, it is impossible 
to estimate what proportion of patients with COPD were 
excluded because of their cardiovascular profi le alone. 
Th e exclusion would leave only 20% to 30% “lower risk” 
patients with COPD eligible for the STATCOPE study. 64  
 An alternative explanation for the discrepancy is that the 
diff erences among COPD subpopulations under consid-
eration may have masked any benefi cial eff ects of statins 
in the STATCOPE study. According to the STATCOPE 
protocol, any patients who met exclusion criteria based 
on the risk-based eligibility for statin therapy during 
follow-up could be prescribed simvastatin and continue in 
the study on an intent-to-treat basis. 63 Th e proportion of 
these patients was not stated in the published STATCOPE 
study fi ndings . If it was large, a dilutional eff ect on 
outcome may have resulted. In addition, patients with 
COPD in the STATCOPE study were representative of 
moderate to severe COPD, albeit the use of supplementary 
oxygen (signifi cantly greater at  . 40%) and duration of 
statin therapy (signifi cantly shorter, with 56%  , 2 years) 
were also substantially diff erent than those in other 
observational studies. 
 Despite its novel fi ndings, our study still has potential 
limitations. Because the present study included only 
patients with GOLD stage II (moderate) COPD, the 
results could not necessarily be extended to patients 
with severe COPD. In addition, because the study had 
a randomized, cross-over design, prolonged carry-over 
eff ects cannot be excluded. However, we attempted to 
minimize this as much as possible by extending the 
washout period for 4 weeks. Finally, the number of 
patients in this study was relatively small and, therefore, 
a larger number of patients with COPD is required for 
the future studies to confi rm our observations and to 
study long-term consequences of statin therapy on 
exacerbations and disease progression. 63 
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